NCT06634927View on ClinicalTrials.gov

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 22, 2024

Primary Completion Date

November 14, 2024

Study Completion Date

February 12, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

Ozempic®

Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.

DRUG

HDG1901

Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.

Trial Locations (1)

230601

The Second Hospital of Anhui Medical University, Hefei

All Listed Sponsors

lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06634927 - Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. | Biotech Hunter | Biotech Hunter